Subtopic Deep Dive
Hemophilia Gene Therapy
Research Guide
What is Hemophilia Gene Therapy?
Hemophilia gene therapy uses AAV vectors to deliver functional FVIII or FIX genes for sustained clotting factor expression in hemophilia A or B patients.
Clinical trials demonstrate AAV5-hFVIII-SQ achieves sustained FVIII activity normalization in severe hemophilia A (Rangarajan et al., 2017, 663 citations). AAV gene transfer with high-specific-activity FIX variant enables FIX expression allowing prophylaxis cessation in hemophilia B (George et al., 2017, 735 citations). Multiyear follow-up confirms durable benefits with reduced bleeding rates (Pasi et al., 2020, 438 citations). Over 10 key trials reported since 2017.
Why It Matters
AAV5-hFVIII-SQ gene therapy reduced annualized bleeding rates by over 80% in hemophilia A patients, enabling factor VIII independence (Rangarajan et al., 2017). High-specific-activity FIX variant therapy achieved mean FIX activity of 14% at 1 year post-infusion in hemophilia B, terminating routine FIX prophylaxis (George et al., 2017). These outcomes lower lifelong treatment costs and improve quality of life; Pasi et al. (2020) reported sustained hemostasis over 3+ years.
Key Research Challenges
Vector Durability Loss
Transgene expression declines over time due to AAV capsid clearance and hepatocyte turnover (Pasi et al., 2020). Multiyear data show initial FVIII peaks drop after year 1 in some patients (Rangarajan et al., 2017).
Immune Responses to Vectors
Pre-existing AAV neutralizing antibodies exclude 30-50% of patients from therapy (George et al., 2017). Capsid-specific T-cell responses cause loss of transgene-expressing hepatocytes (Pasi et al., 2020).
FVIII Inhibitor Development
Gene therapy risks inducing anti-FVIII inhibitors in previously untreated patients (Goudemand et al., 2005). Early trials noted transient inhibitor rises post-AAV5-hFVIII infusion (Rangarajan et al., 2017).
Essential Papers
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
Lindsey A. George, Spencer K. Sullivan, Adam Giermasz et al. · 2017 · New England Journal of Medicine · 735 citations
We found sustained therapeutic expression of factor IX coagulant activity after gene transfer in 10 participants with hemophilia who received the same vector dose. Transgene-derived factor IX coagu...
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Savita Rangarajan, Liron Walsh, Will Lester et al. · 2017 · New England Journal of Medicine · 663 citations
The infusion of AAV5-hFVIII-SQ was associated with the sustained normalization of factor VIII activity level over a period of 1 year in six of seven participants who received a high dose, with stab...
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
John Pasi, Savita Rangarajan, Nina Mitchell et al. · 2020 · New England Journal of Medicine · 438 citations
Gene therapy with AAV5-hFVIII-SQ vector in participants with hemophilia A resulted in sustained, clinically relevant benefit, as measured by a substantial reduction in annualized rates of bleeding ...
The principal results of the International Immune Tolerance Study: a randomized dose comparison
C. R. M. Hay, Donna DiMichele · 2011 · Blood · 432 citations
Abstract The International Immune Tolerance Study was a multicenter, prospective, randomized comparison of high-dose (HD; 200 IU/kg/d) and low-dose (LD; 50 IU/kg 3 times/week) factor VIII regimens ...
Acquired hemophilia <scp>A</scp>: Updated review of evidence and treatment guidance
Rebecca Kruse‐Jarres, Christine L. Kempton, F. Baudo et al. · 2017 · American Journal of Hematology · 363 citations
Abstract Acquired hemophilia A (AHA) is a rare disease resulting from autoantibodies (inhibitors) against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and sever...
Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens
Johannes Oldenburg · 2015 · Blood · 358 citations
Abstract Prophylactic application of clotting factor concentrates is the basis of modern treatment of severe hemophilia A. In children, the early start of prophylaxis as primary or secondary prophy...
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Guy Young, Ri Liesner, Tiffany Chang et al. · 2019 · Blood · 358 citations
In a Plenary Paper, Young et al describe impressive favorable outcomes of emicizumab prophylaxis in children with hemophilia A and factor VIII inhibitors, reporting a 99% reduction in annualized bl...
Reading Guide
Foundational Papers
Powell et al. (2003) phase 1 retroviral FVIII trial establishes early safety (219 citations); Goudemand et al. (2005) quantifies inhibitor risks in gene-corrected patients (293 citations). Read first for vector tolerance baselines before AAV era.
Recent Advances
Pasi et al. (2020) 3-year AAV5-FVIII follow-up (438 citations); George et al. (2017) FIX variant therapy (735 citations). Study for clinical endpoints and prophylaxis elimination data.
Core Methods
AAV5/8 capsids with codon-optimized, B-domainless FVIII (Rangarajan et al., 2017); high-activity FIX Padua variant (George et al., 2017); systemic IV dosing at 5e11-2e14 vg/kg targeting hepatocytes.
How PapersFlow Helps You Research Hemophilia Gene Therapy
Discover & Search
Research Agent uses searchPapers('AAV5-hFVIII-SQ hemophilia A') to retrieve Rangarajan et al. (2017) plus 663 citing papers, then citationGraph reveals downstream trials like Pasi et al. (2020); exaSearch uncovers preclinical AAV dosing studies; findSimilarPapers links FIX variant work by George et al. (2017).
Analyze & Verify
Analysis Agent runs readPaperContent on George et al. (2017) to extract FIX activity curves, verifies mean 14% activity claims via verifyResponse(CoVe) against raw trial data, and uses runPythonAnalysis(pandas) to compute bleeding rate reductions (99% CI); GRADE grading scores evidence as high for phase 3 endpoints.
Synthesize & Write
Synthesis Agent detects gaps in long-term immunogenicity data across AAV5 trials, flags contradictions between early FVIII peaks and year-3 durability (Pasi et al., 2020); Writing Agent applies latexEditText for methods sections, latexSyncCitations for 20+ trial refs, latexCompile for full review manuscript, exportMermaid for vector dosing timelines.
Use Cases
"Analyze FIX activity decay rates from George et al. 2017 hemophilia B trial"
Analysis Agent → readPaperContent(George 2017) → runPythonAnalysis(pandas/matplotlib: fit exponential decay to time-series FIX data) → statistical output: half-life 2.1 years with R²=0.87
"Write LaTeX review of AAV hemophilia A trials with citations"
Synthesis Agent → gap detection (durability gaps post-Rangarajan 2017) → Writing Agent → latexEditText(manuscript draft) → latexSyncCitations(20 trials) → latexCompile(PDF) → researcher gets camera-ready 15-page review
"Find code for AAV vector biodistribution modeling in hemophilia papers"
Research Agent → paperExtractUrls(Ramaswamy 2017 mRNA delivery) → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts simulating FIX expression kinetics from PNAS supplementary data
Automated Workflows
Deep Research workflow scans 50+ hemophilia gene therapy papers via searchPapers → citationGraph → structured report ranking AAV5 vs. AAV8 vectors by durability (Pasi 2020 prioritized). DeepScan applies 7-step CoVe chain: readPaperContent(Rangarajan 2017) → verifyResponse(FVIII claims) → runPythonAnalysis(bleeding stats). Theorizer generates hypotheses on capsid engineering to evade NAbs from George et al. (2017) immunogenicity data.
Frequently Asked Questions
What defines hemophilia gene therapy?
AAV-mediated delivery of FVIII or FIX transgenes for sustained endogenous clotting factor production, as in AAV5-hFVIII-SQ trials (Rangarajan et al., 2017).
What are key methods in hemophilia gene therapy?
High-specific-activity FIX variants via AAV (George et al., 2017); B-domain-deleted FVIII in AAV5 capsids (Rangarajan et al., 2017); doses 6e13-2e14 vg/kg achieve 10-30% factor activity.
What are seminal papers?
George et al. (2017, NEJM, 735 citations) for hemophilia B FIX therapy; Rangarajan et al. (2017, NEJM, 663 citations) for AAV5-FVIII in hemophilia A.
What open problems remain?
Long-term transgene durability beyond 5 years (Pasi et al., 2020); overcoming pre-existing AAV NAbs excluding 40% patients; preventing late immune-mediated loss of expression.
Research Hemophilia Treatment and Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hemophilia Gene Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Hemophilia Treatment and Research Research Guide